DSM-5 cannabis use disorder: A phenotypic and genomic perspective

Arpana Agrawal, Michael T. Lynskey, Kathleen K. Bucholz, Manav Kapoor, Laura Almasy, Danielle M. Dick, Howard Edenberg, Tatiana Foroud, Alison Goate, Dana B. Hancock, Sarah Hartz, Eric O. Johnson, Victor Hesselbrock, John R. Kramer, Samuel Kuperman, John Nurnberger, Marc Schuckit, Laura J. Bierut

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: We explore the factor structure of DSM-5 cannabis use disorders, examine its prevalence across European- and African-American respondents as well as its genetic underpinnings, utilizing data from a genome-wide study of single nucleotide polymorphisms (SNPs). We also estimate the heritability of DSM-5 cannabis use disorders explained by these common SNPs. Methods: Data on 3053 subjects reporting a lifetime history of cannabis use were utilized. Exploratory and confirmatory factor analyses were conducted to create a factor score, which was used in a genome-wide association analysis. p-values from the single SNP analysis were examined for evidence of gene-based association. The aggregate effect of all SNPs was also estimated using Genome-Wide Complex Traits Analysis. Results: The unidimensionality of DSM-5 cannabis use disorder criteria was demonstrated. Comparing DSM-IV to DSM-5, a decrease in prevalence of cannabis use disorders was only noted in European-American respondents and was exceedingly modest. For the DSM-5 cannabis use disorders factor score, no SNP surpassed the genome-wide significance testing threshold. However, in the European-American subsample, gene-based association testing resulted in significant associations in 3 genes (C17orf58, BPTF and PPM1D) on chromosome 17q24. In aggregate, 21% of the variance in DSM-5 cannabis use disorders was explained by the genome-wide SNPs; however, this estimate was not statistically significant. Conclusions: DSM-5 cannabis use disorder represents a unidimensional construct, the prevalence of which is only modestly elevated above the DSM-IV version. Considerably larger sample sizes will be required to identify individual SNPs associated with cannabis use disorders and unequivocally establish its polygenic underpinnings.

Original languageEnglish
Pages (from-to)362-369
Number of pages8
JournalDrug and Alcohol Dependence
Volume134
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Cannabis
Polymorphism
Single Nucleotide Polymorphism
Genes
Nucleotides
Genome
Diagnostic and Statistical Manual of Mental Disorders
Genome-Wide Association Study
Testing
Chromosomes
African Americans
Sample Size
Statistical Factor Analysis

Keywords

  • Association
  • Cannabis
  • DSM-5
  • Genetics
  • GWAS
  • Heritability

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Agrawal, A., Lynskey, M. T., Bucholz, K. K., Kapoor, M., Almasy, L., Dick, D. M., ... Bierut, L. J. (2014). DSM-5 cannabis use disorder: A phenotypic and genomic perspective. Drug and Alcohol Dependence, 134(1), 362-369. https://doi.org/10.1016/j.drugalcdep.2013.11.008

DSM-5 cannabis use disorder : A phenotypic and genomic perspective. / Agrawal, Arpana; Lynskey, Michael T.; Bucholz, Kathleen K.; Kapoor, Manav; Almasy, Laura; Dick, Danielle M.; Edenberg, Howard; Foroud, Tatiana; Goate, Alison; Hancock, Dana B.; Hartz, Sarah; Johnson, Eric O.; Hesselbrock, Victor; Kramer, John R.; Kuperman, Samuel; Nurnberger, John; Schuckit, Marc; Bierut, Laura J.

In: Drug and Alcohol Dependence, Vol. 134, No. 1, 01.01.2014, p. 362-369.

Research output: Contribution to journalArticle

Agrawal, A, Lynskey, MT, Bucholz, KK, Kapoor, M, Almasy, L, Dick, DM, Edenberg, H, Foroud, T, Goate, A, Hancock, DB, Hartz, S, Johnson, EO, Hesselbrock, V, Kramer, JR, Kuperman, S, Nurnberger, J, Schuckit, M & Bierut, LJ 2014, 'DSM-5 cannabis use disorder: A phenotypic and genomic perspective', Drug and Alcohol Dependence, vol. 134, no. 1, pp. 362-369. https://doi.org/10.1016/j.drugalcdep.2013.11.008
Agrawal A, Lynskey MT, Bucholz KK, Kapoor M, Almasy L, Dick DM et al. DSM-5 cannabis use disorder: A phenotypic and genomic perspective. Drug and Alcohol Dependence. 2014 Jan 1;134(1):362-369. https://doi.org/10.1016/j.drugalcdep.2013.11.008
Agrawal, Arpana ; Lynskey, Michael T. ; Bucholz, Kathleen K. ; Kapoor, Manav ; Almasy, Laura ; Dick, Danielle M. ; Edenberg, Howard ; Foroud, Tatiana ; Goate, Alison ; Hancock, Dana B. ; Hartz, Sarah ; Johnson, Eric O. ; Hesselbrock, Victor ; Kramer, John R. ; Kuperman, Samuel ; Nurnberger, John ; Schuckit, Marc ; Bierut, Laura J. / DSM-5 cannabis use disorder : A phenotypic and genomic perspective. In: Drug and Alcohol Dependence. 2014 ; Vol. 134, No. 1. pp. 362-369.
@article{37cc4b20a8a043219bd91d4ed0b4a683,
title = "DSM-5 cannabis use disorder: A phenotypic and genomic perspective",
abstract = "Background: We explore the factor structure of DSM-5 cannabis use disorders, examine its prevalence across European- and African-American respondents as well as its genetic underpinnings, utilizing data from a genome-wide study of single nucleotide polymorphisms (SNPs). We also estimate the heritability of DSM-5 cannabis use disorders explained by these common SNPs. Methods: Data on 3053 subjects reporting a lifetime history of cannabis use were utilized. Exploratory and confirmatory factor analyses were conducted to create a factor score, which was used in a genome-wide association analysis. p-values from the single SNP analysis were examined for evidence of gene-based association. The aggregate effect of all SNPs was also estimated using Genome-Wide Complex Traits Analysis. Results: The unidimensionality of DSM-5 cannabis use disorder criteria was demonstrated. Comparing DSM-IV to DSM-5, a decrease in prevalence of cannabis use disorders was only noted in European-American respondents and was exceedingly modest. For the DSM-5 cannabis use disorders factor score, no SNP surpassed the genome-wide significance testing threshold. However, in the European-American subsample, gene-based association testing resulted in significant associations in 3 genes (C17orf58, BPTF and PPM1D) on chromosome 17q24. In aggregate, 21{\%} of the variance in DSM-5 cannabis use disorders was explained by the genome-wide SNPs; however, this estimate was not statistically significant. Conclusions: DSM-5 cannabis use disorder represents a unidimensional construct, the prevalence of which is only modestly elevated above the DSM-IV version. Considerably larger sample sizes will be required to identify individual SNPs associated with cannabis use disorders and unequivocally establish its polygenic underpinnings.",
keywords = "Association, Cannabis, DSM-5, Genetics, GWAS, Heritability",
author = "Arpana Agrawal and Lynskey, {Michael T.} and Bucholz, {Kathleen K.} and Manav Kapoor and Laura Almasy and Dick, {Danielle M.} and Howard Edenberg and Tatiana Foroud and Alison Goate and Hancock, {Dana B.} and Sarah Hartz and Johnson, {Eric O.} and Victor Hesselbrock and Kramer, {John R.} and Samuel Kuperman and John Nurnberger and Marc Schuckit and Bierut, {Laura J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.drugalcdep.2013.11.008",
language = "English",
volume = "134",
pages = "362--369",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - DSM-5 cannabis use disorder

T2 - A phenotypic and genomic perspective

AU - Agrawal, Arpana

AU - Lynskey, Michael T.

AU - Bucholz, Kathleen K.

AU - Kapoor, Manav

AU - Almasy, Laura

AU - Dick, Danielle M.

AU - Edenberg, Howard

AU - Foroud, Tatiana

AU - Goate, Alison

AU - Hancock, Dana B.

AU - Hartz, Sarah

AU - Johnson, Eric O.

AU - Hesselbrock, Victor

AU - Kramer, John R.

AU - Kuperman, Samuel

AU - Nurnberger, John

AU - Schuckit, Marc

AU - Bierut, Laura J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: We explore the factor structure of DSM-5 cannabis use disorders, examine its prevalence across European- and African-American respondents as well as its genetic underpinnings, utilizing data from a genome-wide study of single nucleotide polymorphisms (SNPs). We also estimate the heritability of DSM-5 cannabis use disorders explained by these common SNPs. Methods: Data on 3053 subjects reporting a lifetime history of cannabis use were utilized. Exploratory and confirmatory factor analyses were conducted to create a factor score, which was used in a genome-wide association analysis. p-values from the single SNP analysis were examined for evidence of gene-based association. The aggregate effect of all SNPs was also estimated using Genome-Wide Complex Traits Analysis. Results: The unidimensionality of DSM-5 cannabis use disorder criteria was demonstrated. Comparing DSM-IV to DSM-5, a decrease in prevalence of cannabis use disorders was only noted in European-American respondents and was exceedingly modest. For the DSM-5 cannabis use disorders factor score, no SNP surpassed the genome-wide significance testing threshold. However, in the European-American subsample, gene-based association testing resulted in significant associations in 3 genes (C17orf58, BPTF and PPM1D) on chromosome 17q24. In aggregate, 21% of the variance in DSM-5 cannabis use disorders was explained by the genome-wide SNPs; however, this estimate was not statistically significant. Conclusions: DSM-5 cannabis use disorder represents a unidimensional construct, the prevalence of which is only modestly elevated above the DSM-IV version. Considerably larger sample sizes will be required to identify individual SNPs associated with cannabis use disorders and unequivocally establish its polygenic underpinnings.

AB - Background: We explore the factor structure of DSM-5 cannabis use disorders, examine its prevalence across European- and African-American respondents as well as its genetic underpinnings, utilizing data from a genome-wide study of single nucleotide polymorphisms (SNPs). We also estimate the heritability of DSM-5 cannabis use disorders explained by these common SNPs. Methods: Data on 3053 subjects reporting a lifetime history of cannabis use were utilized. Exploratory and confirmatory factor analyses were conducted to create a factor score, which was used in a genome-wide association analysis. p-values from the single SNP analysis were examined for evidence of gene-based association. The aggregate effect of all SNPs was also estimated using Genome-Wide Complex Traits Analysis. Results: The unidimensionality of DSM-5 cannabis use disorder criteria was demonstrated. Comparing DSM-IV to DSM-5, a decrease in prevalence of cannabis use disorders was only noted in European-American respondents and was exceedingly modest. For the DSM-5 cannabis use disorders factor score, no SNP surpassed the genome-wide significance testing threshold. However, in the European-American subsample, gene-based association testing resulted in significant associations in 3 genes (C17orf58, BPTF and PPM1D) on chromosome 17q24. In aggregate, 21% of the variance in DSM-5 cannabis use disorders was explained by the genome-wide SNPs; however, this estimate was not statistically significant. Conclusions: DSM-5 cannabis use disorder represents a unidimensional construct, the prevalence of which is only modestly elevated above the DSM-IV version. Considerably larger sample sizes will be required to identify individual SNPs associated with cannabis use disorders and unequivocally establish its polygenic underpinnings.

KW - Association

KW - Cannabis

KW - DSM-5

KW - Genetics

KW - GWAS

KW - Heritability

UR - http://www.scopus.com/inward/record.url?scp=84890221903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890221903&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2013.11.008

DO - 10.1016/j.drugalcdep.2013.11.008

M3 - Article

C2 - 24315570

AN - SCOPUS:84890221903

VL - 134

SP - 362

EP - 369

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1

ER -